Dashboard
Manage Tickers

TRDA Entrada Therapeutics, Inc.

Nasdaq entradatx.com


$ 6.82 $ 0.43 (6.72 %)    

Friday, 24-Oct-2025 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 6.83
$ 6.51
$ 6.40 x 1
$ 6.93 x 5
$ 6.41 - $ 6.87
$ 4.93 - $ 21.79
222,354
na
259.79M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 12-09-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

entrada-therapeutics-awards-50000-dreams-grants-to-jett-foundation-us-and-parent-project-aps-italy-to-advance-equity-accessibility-and-inclusion-for-duchenne-community
Entrada Therapeutics Awards $50,000 DREAMS...
09/05/2025 11:03:32

entrada-therapeutics-q2-eps-104-misses-085-estimate-sales-1950m-miss-9651m-estimate
Entrada Therapeutics Q2 EPS $(1.04) Misses...
08/06/2025 11:34:11

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate o...

entrada-therapeutics-receives-authorization-in-the-eu-to-initiate-the-elevate-45-201-phase-12-multiple-ascending-dose-clinical-study-of-entr-601-45-in-patients-with-duchenne-muscular-dystrophy-amenable-to-exon-45-skipping
Entrada Therapeutics Receives Authorizatio...
05/28/2025 11:05:51

hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Entr...
05/20/2025 10:48:32

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

entrada-therapeutics-q1-eps-042-beats-076-estimate-sales-2056m-beat-1017m-estimate
Entrada Therapeutics Q1 EPS $(0.42) Beats ...
05/08/2025 11:16:39

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Entr...
03/31/2025 11:11:36

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

entrada-receives-authorization-from-uk-mhra-and-research-ethics-committee-to-initiate-elevate-45-201
Entrada Receives Authorization From UK MHR...
03/24/2025 11:22:15

ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal ...

entrada-therapeutics-expects-csh-runway-into-q2-2027-with-420m-in-cash-and-equivalents-as-of-december-31-2024
Entrada Therapeutics Expects Csh Runway In...
02/27/2025 12:24:14

entrada-therapeutics-q4-2024-gaap-eps-003-beats-067-estimate-sales-3740m-beat-1312m-estimate
Entrada Therapeutics Q4 2024 GAAP EPS $0.0...
02/27/2025 12:09:56

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of ...

hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Entr...
02/25/2025 12:29:38

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

fda-clears-entrada-therapeutics-early-stage-for-potential-treatment-of-duchenne-muscular-dystrophy
FDA Clears Entrada Therapeutics' Early-Sta...
02/24/2025 15:03:18

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscul...

entrada-therapeutics-reveals-fda-removal-of-clinical-hold-on-entr-601-44
Entrada Therapeutics Reveals FDA Removal O...
02/24/2025 12:01:59

"Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in...

hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Entr...
02/04/2025 11:58:03

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

entrada-therapeutics-gets-uk-approval-to-launch-phase-12-trial-for-duchenne-muscular-dystrophy-treatment
Entrada Therapeutics Gets UK Approval to L...
02/03/2025 12:09:54

Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the United Kingdom's Medicines ...

beyond-the-numbers-4-analysts-discuss-entrada-therapeutics-stock
Beyond The Numbers: 4 Analysts Discuss Ent...
11/06/2024 16:00:29

oppenheimer-maintains-outperform-on-entrada-therapeutics-raises-price-target-to-28
Oppenheimer Maintains Outperform on Entrad...
11/06/2024 14:08:36

Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and raises the price t...

hc-wainwright--co-maintains-buy-on-entrada-therapeutics-raises-price-target-to-20
HC Wainwright & Co. Maintains Buy on Entra...
11/06/2024 12:35:54

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and raises the pr...

entrada-therapeutics-says-cash-runway-expected-into-2027-with-449m-in-cash-cash-equivalents-and-marketable-securities-as-of-september-30-2024
Entrada Therapeutics Says Cash Runway Expe...
11/05/2024 12:26:58

entrada-therapeutics-q3-2024-gaap-eps-035-beats-078-estimate-sales-1957m-beat-1232m-estimate
Entrada Therapeutics Q3 2024 GAAP EPS $(0....
11/05/2024 12:26:10

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of ...

entrada-therapeutics-announced-the-presentation-of-clinical-and-preclinical-data-supporting-its-expanding-duchenne-franchise-at-the-annual-congress-of-the-world-muscle-society
Entrada Therapeutics Announced The Present...
10/09/2024 11:15:11

Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION